1
|
Bhasin S, Das A. Marine alkaloid rigidin analogues as potential selective inhibitors of SHP1, a new strategy for cancer immunotherapeutics. J Biomol Struct Dyn 2024; 42:5590-5606. [PMID: 37349914 DOI: 10.1080/07391102.2023.2227708] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2023] [Accepted: 06/14/2023] [Indexed: 06/24/2023]
Abstract
SHP1 is a protein tyrosine phosphatase playing a central role in immunity, cell growth, development, and survival. The inhibition of SHP1 can help in better prognosis in various disorders like breast and ovarian cancer, melanoma, atherosclerosis, hypoxia, hypoactive immune response, and familial dysautonomia. The currently available inhibitors of SHP1 have the side effect of inhibiting the activity of SHP2, which shares >60% sequence similarity with SHP1 but has distinct biological functions. Thus, there is a need to search for novel specific inhibitors of SHP1. The current study uses a combination of virtual screening and molecular dynamic simulations, followed by PCA and MM-GBSA analysis, to screen about 35000 compounds; to predict that two rigidin analogues can potentially selectively inhibit SHP1 but not SHP2. Our studies demonstrate that these rigidin analogues are more potent at inhibiting SHP1 than the commercially available inhibitor NSC-87877. Further, cross-binding studies with SHP2 exhibited poor binding efficiency and lower stability of the complex, thus indicating a specificity of the rigidin analogues for SHP1, which is crucial in preventing side effects due to the diverse physiological functions of SHP2 in cellular signaling, proliferation, and hematopoiesis. Additionally, SHP1 is essential in mediating the inhibitory signaling in antitumor immune cells like NK and T cells. Hence, the rigidin analogues that inhibit SHP1 will potentiate the anti-tumor immune response by the release of inhibitory function of NK cells, thus driving NK activating response, in addition to their intrinsic anti-tumor function. Thus, SHP1 inhibition is a novel double-blade approach towards anti-cancer immunotherapeutics.Communicated by Ramaswamy H. Sarma.
Collapse
Affiliation(s)
- Sidharth Bhasin
- Kusuma School of Biological Sciences, Indian Institute of Technology Delhi, New Delhi, India
- Department of Biotechnology, Delhi Technological University, Shahbad Daulatpur, Delhi, India
| | - Asmita Das
- Department of Biotechnology, Delhi Technological University, Shahbad Daulatpur, Delhi, India
| |
Collapse
|
2
|
van der Westhuyzen A, Ashraf N, Conradie D, Loots L, Kaschula CH, Pelly SC, Frolova LV, Landfair T, Shuster CB, Betancourt T, Kornienko A, van Otterlo WAL. Improved Rigidin-Inspired Antiproliferative Agents with Modifications on the 7-Deazahypoxanthine C7/C8 Ring Systems. J Med Chem 2024; 67:9950-9975. [PMID: 38865195 PMCID: PMC11215747 DOI: 10.1021/acs.jmedchem.3c02473] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2023] [Revised: 06/02/2024] [Accepted: 06/04/2024] [Indexed: 06/14/2024]
Abstract
To improve their aqueous solubility characteristics, water-solubilizing groups were added to some antiproliferative, rigidin-inspired 7-deazahypoxanthine frameworks after molecular modeling seemed to indicate that structural modifications on the C7 and/or C8 phenyl groups would be beneficial. To this end, two sets of 7-deazahypoxanthines were synthesized by way of a multicomponent reaction approach. It was subsequently determined that their antiproliferative activity against HeLa cells was retained for those derivatives with a glycol ether at the 4'-position of the C8 aryl ring system, while also significantly improving their solubility behavior. The best of these compounds were the equipotent 6-[4-(2-ethoxyethoxy)benzoyl]-2-(pent-4-yn-1-yl)-5-phenyl-1,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 33 and 6-[4-(2-ethoxyethoxy)benzoyl]-5-(3-fluorophenyl)-2-(pent-4-yn-1-yl)-1,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 59. Similarly to the parent 1, the new derivatives were also potent inhibitors of tubulin assembly. In treated HeLa cells, live cell confocal microscopy demonstrated their impact on microtubulin dynamics and spindle morphology, which is the upstream trigger of mitotic delay and cell death.
Collapse
Affiliation(s)
| | - Naghmana Ashraf
- Department
of Biology, New Mexico State University, Las Cruces ,New Mexico 88003, United States
| | - Daleen Conradie
- Department
of Chemistry and Polymer Science, Stellenbosch
University, Stellenbosch 7600, South Africa
- Department
of Physiological Sciences, Stellenbosch
University, Stellenbosch 7600, South Africa
| | - Leigh Loots
- Department
of Chemistry and Polymer Science, Stellenbosch
University, Stellenbosch 7600, South Africa
| | - Catherine H. Kaschula
- Department
of Chemistry and Polymer Science, Stellenbosch
University, Stellenbosch 7600, South Africa
| | - Stephen C. Pelly
- Department
of Chemistry and Polymer Science, Stellenbosch
University, Stellenbosch 7600, South Africa
- Department
of Chemistry, Emory University, 1515 Dickey Drive ,Atlanta ,Georgia 30322, United States
| | - Liliya V. Frolova
- Department
of Chemistry and Biochemistry, Purdue University, 2101 East Coliseum Blvd. ,Fort Wayne ,Indiana 46805, United States
| | - Taylor Landfair
- Department
of Biology, New Mexico State University, Las Cruces ,New Mexico 88003, United States
| | - Charles B. Shuster
- Department
of Biology, New Mexico State University, Las Cruces ,New Mexico 88003, United States
| | - Tania Betancourt
- Department
of Chemistry and Biochemistry, Texas State
University, San Marcos ,Texas 78666, United States
| | - Alexander Kornienko
- Department
of Chemistry and Biochemistry, Texas State
University, San Marcos ,Texas 78666, United States
| | - Willem A. L. van Otterlo
- Department
of Chemistry and Polymer Science, Stellenbosch
University, Stellenbosch 7600, South Africa
| |
Collapse
|
3
|
Yang H, Zhang D, Yuan Z, Qiao H, Xia Z, Cao F, Lu Y, Jiang F. Novel 4-Aryl-4H-chromene derivative displayed excellent in vivo anti-glioblastoma efficacy as the microtubule-targeting agent. Eur J Med Chem 2024; 267:116205. [PMID: 38350361 DOI: 10.1016/j.ejmech.2024.116205] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2023] [Revised: 01/23/2024] [Accepted: 01/31/2024] [Indexed: 02/15/2024]
Abstract
In this study, a series of novel 4-Aryl-4H-chromene derivatives (D1-D31) were designed and synthesized by integrating quinoline heterocycle to crolibulin template molecule based on the strategy of molecular hybridization. One of these compounds D19 displayed positive antiproliferative activity against U87 cancer cell line (IC50 = 0.90 ± 0.03 μM). Compound D19 was verified as the microtubule-targeting agent through downregulating tubulin related genes of U87 cells, destroying the cytoskeleton of tubulins and interacting with the colchicine-binding site to inhibit the polymerization of tubulins by transcriptome analysis, immune-fluorescence staining, microtubule dynamics and EBI competition assays as well as molecular docking simulations. Moreover, compound D19 induced G2/M phase arrest, resulted in cell apoptosis and inhibited the migration of U87 cells by flow cytometry analysis and wound healing assays. Significantly, compound D19 dose-dependently inhibited the tumor growth of orthotopic glioma xenografts model (GL261-Luc) and effectively prolonged the survival time of mice, which were extremely better than those of positive drug temozolomide (TMZ). Compound D19 exhibited potent in vivo antivascular activity as well as no observable toxicity. Furthermore, the results of in silico simulation studies and P-gp transwell assays verified the positive correlation between compound D19's Blood-Brain Barrier (BBB) permeability and its in vivo anti-GBM activity. Overall, compound D19 can be used as a promising anti-GBM lead compound for the treatment of glioblastoma.
Collapse
Affiliation(s)
- Haoyi Yang
- School of Life Science and Technology, China Pharmaceutical University, Nanjing, 210009, China
| | - Dongyu Zhang
- School of Engineering, China Pharmaceutical University, Nanjing, 210009, China
| | - Ziyang Yuan
- School of Engineering, China Pharmaceutical University, Nanjing, 210009, China
| | - Haishi Qiao
- School of Engineering, China Pharmaceutical University, Nanjing, 210009, China
| | - Zhuolu Xia
- School of Engineering, China Pharmaceutical University, Nanjing, 210009, China
| | - Feng Cao
- School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, China.
| | - Yuanyuan Lu
- School of Life Science and Technology, China Pharmaceutical University, Nanjing, 210009, China.
| | - Feng Jiang
- School of Engineering, China Pharmaceutical University, Nanjing, 210009, China.
| |
Collapse
|
4
|
Bretin L, Husiev Y, Ramu V, Zhang L, Hakkennes M, Abyar S, Johns AC, Le Dévédec SE, Betancourt T, Kornienko A, Bonnet S. Red-Light Activation of a Microtubule Polymerization Inhibitor via Amide Functionalization of the Ruthenium Photocage. Angew Chem Int Ed Engl 2024; 63:e202316425. [PMID: 38061013 DOI: 10.1002/anie.202316425] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2023] [Indexed: 12/21/2023]
Abstract
Photoactivated chemotherapy (PACT) is a promising cancer treatment modality that kills cancer cells via photochemical uncaging of a cytotoxic drug. Most ruthenium-based photocages used for PACT are activated with blue or green light, which penetrates sub-optimally into tumor tissues. Here, we report amide functionalization as a tool to fine-tune the toxicity and excited states of a terpyridine-based ruthenium photocage. Due to conjugation of the amide group with the terpyridine π system in the excited state, the absorption of red light (630 nm) increased 8-fold, and the photosubstitution rate rose 5-fold. In vitro, red light activation triggered inhibition of tubulin polymerization, which led to apoptotic cell death both in normoxic (21 % O2 ) and hypoxic (1 % O2 ) cancer cells. In vivo, red light irradiation of tumor-bearing mice demonstrated significant tumor volume reduction (45 %) with improved biosafety, thereby demonstrating the clinical potential of this compound.
Collapse
Affiliation(s)
- Ludovic Bretin
- Leiden Institute of Chemistry, Leiden University, Gorlaeus Laboratories, PO Box 9502, 2300, RA Leiden, The Netherlands
| | - Yurii Husiev
- Leiden Institute of Chemistry, Leiden University, Gorlaeus Laboratories, PO Box 9502, 2300, RA Leiden, The Netherlands
| | - Vadde Ramu
- Leiden Institute of Chemistry, Leiden University, Gorlaeus Laboratories, PO Box 9502, 2300, RA Leiden, The Netherlands
| | - Liyan Zhang
- Leiden Institute of Chemistry, Leiden University, Gorlaeus Laboratories, PO Box 9502, 2300, RA Leiden, The Netherlands
| | - Matthijs Hakkennes
- Leiden Institute of Chemistry, Leiden University, Gorlaeus Laboratories, PO Box 9502, 2300, RA Leiden, The Netherlands
| | - Selda Abyar
- Leiden Institute of Chemistry, Leiden University, Gorlaeus Laboratories, PO Box 9502, 2300, RA Leiden, The Netherlands
| | - Andrew C Johns
- Department of Chemistry and Biochemistry, Texas State University, 601 University Dr., San Marcos, TX 78666, USA
| | - Sylvia E Le Dévédec
- Leiden Academic Centre for Drug Research, Leiden University, Gorlaeus Laboratories, PO Box 9502, 2300, RA Leiden, The Netherlands
| | - Tania Betancourt
- Department of Chemistry and Biochemistry, Texas State University, 601 University Dr., San Marcos, TX 78666, USA
| | - Alexander Kornienko
- Department of Chemistry and Biochemistry, Texas State University, 601 University Dr., San Marcos, TX 78666, USA
| | - Sylvestre Bonnet
- Leiden Institute of Chemistry, Leiden University, Gorlaeus Laboratories, PO Box 9502, 2300, RA Leiden, The Netherlands
| |
Collapse
|
5
|
Bereiter R, Oberlechner M, Micura R. A new route for the synthesis of 1-deazaguanine and 1-deazahypoxanthine. Beilstein J Org Chem 2022; 18:1617-1624. [DOI: 10.3762/bjoc.18.172] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2022] [Accepted: 11/17/2022] [Indexed: 11/30/2022] Open
Abstract
Imidazopyridines and pyrrolopyrimidines are an important class of compounds in medicinal chemistry. They can also be considered as deaza-modified purine nucleobases, and as such have attracted a lot of interest recently in the context of RNA atomic mutagenesis. In particular, for 1-deazaguanine (c1G base), a significant increase in demand is apparent. Synthetic access is challenging and the few reports found in the literature suffer from the requirement of hazardous intermediates and harsh reaction conditions. Here, we report a new six-step synthesis for c1G base, starting from 6-iodo-1-deazapurine. The key transformations are copper catalyzed C–O-bond formation followed by site-specific nitration. A further strength of our route is divergency, additionally enabling the synthesis of 1-deazahypoxanthine (c1I base).
Collapse
|
6
|
Thakur A, Faujdar C, Sharma R, Sharma S, Malik B, Nepali K, Liou JP. Glioblastoma: Current Status, Emerging Targets, and Recent Advances. J Med Chem 2022; 65:8596-8685. [PMID: 35786935 PMCID: PMC9297300 DOI: 10.1021/acs.jmedchem.1c01946] [Citation(s) in RCA: 28] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
![]()
Glioblastoma (GBM) is a highly malignant
brain tumor characterized
by a heterogeneous population of genetically unstable and highly infiltrative
cells that are resistant to chemotherapy. Although substantial efforts
have been invested in the field of anti-GBM drug discovery in the
past decade, success has primarily been confined to the preclinical
level, and clinical studies have often been hampered due to efficacy-,
selectivity-, or physicochemical property-related issues. Thus, expansion
of the list of molecular targets coupled with a pragmatic design of
new small-molecule inhibitors with central nervous system (CNS)-penetrating
ability is required to steer the wheels of anti-GBM drug discovery
endeavors. This Perspective presents various aspects of drug discovery
(challenges in GBM drug discovery and delivery, therapeutic targets,
and agents under clinical investigation). The comprehensively covered
sections include the recent medicinal chemistry campaigns embarked
upon to validate the potential of numerous enzymes/proteins/receptors
as therapeutic targets in GBM.
Collapse
Affiliation(s)
- Amandeep Thakur
- School of Pharmacy, College of Pharmacy, Taipei Medical University, 250 Wuxing Street, Taipei 11031, Taiwan
| | - Chetna Faujdar
- Department of Biotechnology, Jaypee Institute of Information Technology, Noida 201307, India
| | - Ram Sharma
- School of Pharmacy, College of Pharmacy, Taipei Medical University, 250 Wuxing Street, Taipei 11031, Taiwan
| | - Sachin Sharma
- School of Pharmacy, College of Pharmacy, Taipei Medical University, 250 Wuxing Street, Taipei 11031, Taiwan
| | - Basant Malik
- Department of Sterile Product Development, Research and Development-Unit 2, Jubiliant Generics Ltd., Noida 201301, India
| | - Kunal Nepali
- School of Pharmacy, College of Pharmacy, Taipei Medical University, 250 Wuxing Street, Taipei 11031, Taiwan
| | - Jing Ping Liou
- School of Pharmacy, College of Pharmacy, Taipei Medical University, 250 Wuxing Street, Taipei 11031, Taiwan
| |
Collapse
|
7
|
Khotimchenko R, Bryukhovetskiy I, Khotimchenko M, Khotimchenko Y. Bioactive Compounds with Antiglioma Activity from Marine Species. Biomedicines 2021; 9:biomedicines9080886. [PMID: 34440090 PMCID: PMC8389718 DOI: 10.3390/biomedicines9080886] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2021] [Revised: 07/20/2021] [Accepted: 07/21/2021] [Indexed: 11/21/2022] Open
Abstract
The search for new chemical compounds with antitumor pharmacological activity is a necessary process for creating more effective drugs for each specific malignancy type. This review presents the outcomes of screening studies of natural compounds with high anti-glioma activity. Despite significant advances in cancer therapy, there are still some tumors currently considered completely incurable including brain gliomas. This review covers the main problems of the glioma chemotherapy including drug resistance, side effects of common anti-glioma drugs, and genetic diversity of brain tumors. The main emphasis is made on the characterization of natural compounds isolated from marine organisms because taxonomic diversity of organisms in seawaters significantly exceeds that of terrestrial species. Thus, we should expect greater chemical diversity of marine compounds and greater likelihood of finding effective molecules with antiglioma activity. The review covers at least 15 classes of organic compounds with their chemical formulas provided as well as semi-inhibitory concentrations, mechanisms of action, and pharmacokinetic profiles. In conclusion, the analysis of the taxonomic diversity of marine species containing bioactives with antiglioma activity is performed noting cytotoxicity indicators and to the tumor cells in comparison with similar indicators of antitumor agents approved for clinical use as antiglioblastoma chemotherapeutics.
Collapse
Affiliation(s)
- Rodion Khotimchenko
- School of Biomedicine, Far Eastern Federal University, 690090 Vladivostok, Russia; (R.K.); (I.B.); (M.K.)
| | - Igor Bryukhovetskiy
- School of Biomedicine, Far Eastern Federal University, 690090 Vladivostok, Russia; (R.K.); (I.B.); (M.K.)
| | - Maksim Khotimchenko
- School of Biomedicine, Far Eastern Federal University, 690090 Vladivostok, Russia; (R.K.); (I.B.); (M.K.)
| | - Yuri Khotimchenko
- School of Biomedicine, Far Eastern Federal University, 690090 Vladivostok, Russia; (R.K.); (I.B.); (M.K.)
- Laboratory of Pharmacology, A. V. Zhirmunsky National Center of Marine Biology, Far Eastern Branch, Russian Academy of Sciences, 690950 Vladivostok, Russia
- Correspondence:
| |
Collapse
|
8
|
Zhou S, Huang G, Chen G. Synthesis and anti-tumor activity of marine alkaloids. Bioorg Med Chem Lett 2021; 41:128009. [DOI: 10.1016/j.bmcl.2021.128009] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2020] [Revised: 03/20/2021] [Accepted: 03/28/2021] [Indexed: 12/16/2022]
|
9
|
Matulja D, Wittine K, Malatesti N, Laclef S, Turks M, Markovic MK, Ambrožić G, Marković D. Marine Natural Products with High Anticancer Activities. Curr Med Chem 2020; 27:1243-1307. [PMID: 31931690 DOI: 10.2174/0929867327666200113154115] [Citation(s) in RCA: 27] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2019] [Revised: 12/03/2019] [Accepted: 12/15/2019] [Indexed: 12/13/2022]
Abstract
This review covers recent literature from 2012-2019 concerning 170 marine natural products and their semisynthetic analogues with strong anticancer biological activities. Reports that shed light on cellular and molecular mechanisms and biological functions of these compounds, thus advancing the understanding in cancer biology are also included. Biosynthetic studies and total syntheses, which have provided access to derivatives and have contributed to the proper structure or stereochemistry elucidation or revision are mentioned. The natural compounds isolated from marine organisms are divided into nine groups, namely: alkaloids, sterols and steroids, glycosides, terpenes and terpenoids, macrolides, polypeptides, quinones, phenols and polyphenols, and miscellaneous products. An emphasis is placed on several drugs originating from marine natural products that have already been marketed or are currently in clinical trials.
Collapse
Affiliation(s)
- Dario Matulja
- Department of Biotechnology, University of Rijeka, Radmile Matejcic 2, 51000 Rijeka, Croatia
| | - Karlo Wittine
- Department of Biotechnology, University of Rijeka, Radmile Matejcic 2, 51000 Rijeka, Croatia
| | - Nela Malatesti
- Department of Biotechnology, University of Rijeka, Radmile Matejcic 2, 51000 Rijeka, Croatia
| | - Sylvain Laclef
- Laboratoire de Glycochimie, des Antimicrobiens et des Agro-ressources (LG2A), CNRS FRE 3517, 33 rue Saint-Leu, 80039 Amiens, France
| | - Maris Turks
- Faculty of Material Science and Applied Chemistry, Riga Technical University, P. Valdena Str. 3, Riga, LV-1007, Latvia
| | - Maria Kolympadi Markovic
- Department of Physics, and Center for Micro- and Nanosciences and Technologies, University of Rijeka, Radmile Matejcic 2, 51000 Rijeka, Croatia
| | - Gabriela Ambrožić
- Department of Physics, and Center for Micro- and Nanosciences and Technologies, University of Rijeka, Radmile Matejcic 2, 51000 Rijeka, Croatia
| | - Dean Marković
- Department of Biotechnology, University of Rijeka, Radmile Matejcic 2, 51000 Rijeka, Croatia
| |
Collapse
|
10
|
Zhou S, Huang G. Retracted Article: The synthesis and biological activity of marine alkaloid derivatives and analogues. RSC Adv 2020; 10:31909-31935. [PMID: 35518151 PMCID: PMC9056551 DOI: 10.1039/d0ra05856d] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2020] [Accepted: 07/29/2020] [Indexed: 12/11/2022] Open
Abstract
The ocean is the origin of life, with a unique ecological environment, which has given birth to a wealth of marine organisms. The ocean is an important source of biological resources and tens of thousands of monomeric compounds have been separated from marine organisms using modern separation technology. Most of these monomeric compounds have some kind of biological activity that has attracted extensive attention from researchers. Marine alkaloids are a kind of compound that can be separated from marine organisms. They have complex and special chemical structures, but at the same time, they can show diversity in biological activities. The biological activities of marine alkaloids mainly manifest in the form of anti-tumor, anti-fungus, anti-viral, anti-malaria, and anti-osteoporosis properties. Many marine alkaloids have good medicinal prospects and can possibly be used as anti-tumor, anti-viral, and anti-fungal clinical drugs or as lead compounds. The limited amounts of marine alkaloids that can be obtained by separation, coupled with the high cytotoxicity and low selectivity of these lead compounds, has restricted the clinical research and industrial development of marine alkaloids. Marine alkaloid derivatives and analogues have been obtained via rational drug design and chemical synthesis, to make up for the shortcomings of marine alkaloids; this has become an urgent subject for research and development. This work systematically reviews the recent developments relating to marine alkaloid derivatives and analogues in the field of medical chemistry over the last 10 years (2010–2019). We divide marine alkaloid derivatives and analogues into five types from the point-of-view of biological activity and elaborated on these activities. We also briefly discuss the optimization process, chemical synthesis, biological activity evaluation, and structure–activity relationship (SAR) of each of these compounds. The abundant SAR data provides reasonable approaches for the design and development of new biologically active marine alkaloid derivatives and analogues. The ocean is the origin of life, with a unique ecological environment, which has given birth to a wealth of marine organisms.![]()
Collapse
Affiliation(s)
- Shiyang Zhou
- Chongqing Key Laboratory of Green Synthesis and Application
- Active Carbohydrate Research Institute
- College of Chemistry
- Chongqing Normal University
- Chongqing 401331
| | - Gangliang Huang
- Chongqing Key Laboratory of Green Synthesis and Application
- Active Carbohydrate Research Institute
- College of Chemistry
- Chongqing Normal University
- Chongqing 401331
| |
Collapse
|
11
|
Dasari R, Błauż A, Medellin DC, Kassim RM, Viera C, Santarosa M, van der Westhuyzen AE, van Otterlo WAL, Olivas T, Yildiz T, Betancourt T, Shuster CB, Rogelj S, Rychlik B, Hudnall T, Frolova LV, Kornienko A. Microtubule-Targeting 7-Deazahypoxanthines Derived from Marine Alkaloid Rigidins: Exploration of the N3 and N9 Positions and Interaction with Multidrug-Resistance Proteins. ChemMedChem 2019; 14:322-333. [PMID: 30562414 PMCID: PMC6476547 DOI: 10.1002/cmdc.201800658] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2018] [Revised: 12/17/2018] [Indexed: 12/12/2022]
Abstract
Our laboratories have been investigating synthetic analogues of marine alkaloid rigidins that possess promising anticancer activities. These analogues, based on the 7-deazahypoxanthine skeleton, are available in one- or two-step synthetic sequences and exert cytotoxicity by disrupting microtubule dynamics in cancer cells. In the present work we extended the available structure-activity relationship (SAR) data to N3- and N9-substituted derivatives. Although N3 substitution results in loss of activity, the N9-substituted compounds retain nanomolar antiproliferative activities and the anti-tubulin mode of action of the original unsubstituted compounds. Furthermore, our results also demonstrate that multidrug-resistance (MDR) proteins do not confer resistance to both N9-unsubstituted and -substituted compounds. It was found that sublines overexpressing ABCG2, ABCC1, and ABCB1 proteins are as responsive to the rigidin analogues as their parental cell lines. Thus, the study reported herein provides further impetus to investigate the rigidin-inspired 7-deazahypoxanthines as promising anticancer agents.
Collapse
Affiliation(s)
- Ramesh Dasari
- Department of Chemistry and Biochemistry, Texas State University, San Marcos, TX, 78666, USA
| | - Andrzej Błauż
- Cytometry Lab, Department of Molecular Biophysics, Faculty of Biology and Environmental Protection, University of Łódź, ul. Pomorska 141/143, 90-236, Łódź, Poland
| | - Derek C Medellin
- Department of Chemistry and Biochemistry, Texas State University, San Marcos, TX, 78666, USA
| | - Roaa M Kassim
- Department of Biology, New Mexico State University, Las Cruces, NM, 88003, USA
| | - Carlos Viera
- Departments of Chemistry and Biology, New Mexico Tech, Socorro, NM, 87801, USA
| | - Maximo Santarosa
- Departments of Chemistry and Biology, New Mexico Tech, Socorro, NM, 87801, USA
| | - Alet E van der Westhuyzen
- Department of Chemistry and Polymer Science, University of Stellenbosch, 7602, Stellenbosch, South Africa
| | - Willem A L van Otterlo
- Department of Chemistry and Polymer Science, University of Stellenbosch, 7602, Stellenbosch, South Africa
| | - Taryn Olivas
- Department of Chemistry and Biochemistry, Texas State University, San Marcos, TX, 78666, USA
| | - Tugba Yildiz
- Materials Science and Engineering Program, Texas State University, San Marcos, TX, 78666, USA
| | - Tania Betancourt
- Department of Chemistry and Biochemistry, Texas State University, San Marcos, TX, 78666, USA
- Materials Science and Engineering Program, Texas State University, San Marcos, TX, 78666, USA
| | - Charles B Shuster
- Department of Biology, New Mexico State University, Las Cruces, NM, 88003, USA
| | - Snezna Rogelj
- Departments of Chemistry and Biology, New Mexico Tech, Socorro, NM, 87801, USA
| | - Błażej Rychlik
- Cytometry Lab, Department of Molecular Biophysics, Faculty of Biology and Environmental Protection, University of Łódź, ul. Pomorska 141/143, 90-236, Łódź, Poland
| | - Todd Hudnall
- Department of Chemistry and Biochemistry, Texas State University, San Marcos, TX, 78666, USA
| | - Liliya V Frolova
- Departments of Chemistry and Biology, New Mexico Tech, Socorro, NM, 87801, USA
| | - Alexander Kornienko
- Department of Chemistry and Biochemistry, Texas State University, San Marcos, TX, 78666, USA
| |
Collapse
|
12
|
Fernandes GFDS, Fernandes BC, Valente V, Dos Santos JL. Recent advances in the discovery of small molecules targeting glioblastoma. Eur J Med Chem 2018; 164:8-26. [PMID: 30583248 DOI: 10.1016/j.ejmech.2018.12.033] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2018] [Revised: 12/13/2018] [Accepted: 12/14/2018] [Indexed: 12/22/2022]
Abstract
Glioblastoma (GBM) is one of the most common central nervous system cancers. It is characterized as a fast-growing tumor that arises from multiple cell types with neural stem-cell-like properties. Additionally, GBM tumors are highly invasive, which is attributed to the presence of glioblastoma stem cells that makes surgery ineffective in most cases. Currently, temozolomide is the unique chemotherapy option approved by the U.S. Food and Drug Administration for GBM treatment. This review analyzes the emergence and development of new synthetic small molecules discovered as promising anti-glioblastoma agents. A number of compounds were described herein and grouped according to the main chemical class used in the drug discovery process. Importantly, we focused only on synthetic compounds published in the last 10 years, thus excluding natural products. Furthermore, we included in this review only those most biologically active compounds with proven in vitro and/or in vivo efficacy.
Collapse
Affiliation(s)
- Guilherme Felipe Dos Santos Fernandes
- São Paulo State University (UNESP), School of Pharmaceutical Sciences, Araraquara, 14800-903, Brazil; São Paulo State University (UNESP), Institute of Chemistry, Araraquara, 14800-060, Brazil
| | - Barbara Colatto Fernandes
- São Paulo State University (UNESP), School of Pharmaceutical Sciences, Araraquara, 14800-903, Brazil
| | - Valeria Valente
- São Paulo State University (UNESP), School of Pharmaceutical Sciences, Araraquara, 14800-903, Brazil
| | - Jean Leandro Dos Santos
- São Paulo State University (UNESP), School of Pharmaceutical Sciences, Araraquara, 14800-903, Brazil; São Paulo State University (UNESP), Institute of Chemistry, Araraquara, 14800-060, Brazil.
| |
Collapse
|
13
|
Pathania S, Rawal RK. Pyrrolopyrimidines: An update on recent advancements in their medicinal attributes. Eur J Med Chem 2018; 157:503-526. [PMID: 30114661 DOI: 10.1016/j.ejmech.2018.08.023] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2018] [Revised: 08/06/2018] [Accepted: 08/08/2018] [Indexed: 01/09/2023]
Abstract
Fused heterocycles are reported to demonstrate variety of biological activities such as anticancer, antibacterial, antifungal and anti-inflammatory, and are thus exhaustively utilized in the field of medicinal chemistry. Pyrrolopyrimidines is one of the major classes of fused heterocycles which are extensively reported throughout the literature. Several reports suggest that pyrrolopyrimidine as fused scaffold possess more diverse and potent pharmacological profile than individual pyrrole and pyrimidine nucleus. Different pathological targets require different structural attributes reflected via varied substitutions, thus in recent years, researchers have employed various synthetic strategies to achieve desired substitutions on the pyrrolopyrimidine nucleus. In this review, authors highlight the recent advancement in this area, special focus was laid on the pharmacological profile and structure-activity relationship studies (SAR) of various synthesized pyrrolopyrimidine derivatives.
Collapse
Affiliation(s)
- Shelly Pathania
- Department of Pharmaceutical Chemistry, Indo-Soviet Friendship College of Pharmacy (ISFCP), Moga, 142001, India; Department of Pharmaceutical Sciences and Technology, Maharaja Ranjit Singh Punjab Technical University, Bathinda, 151001, Punjab, India
| | - Ravindra K Rawal
- Department of Chemistry, Maharishi Markandeshwar (Deemed to be University), Mullana, 133207, Ambala, Haryana, India.
| |
Collapse
|
14
|
van der Westhuyzen AE, Frolova LV, Kornienko A, van Otterlo WAL. The Rigidins: Isolation, Bioactivity, and Total Synthesis-Novel Pyrrolo[2,3-d]Pyrimidine Analogues Using Multicomponent Reactions. THE ALKALOIDS. CHEMISTRY AND BIOLOGY 2018; 79:191-220. [PMID: 29455836 DOI: 10.1016/bs.alkal.2017.12.003] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
Rigidins (2-6) are pyrrolopyrimidine alkaloids isolated from marine tunicates. Since their isolation, refinement of their total syntheses, and biochemical evaluation, interest toward this pyrrolo[2,3-d]pyrimidine scaffold as a medicinal candidate has been triggered. The derivatization of these natural products has led to the discovery of a novel range of 7-deazahypoxanthines, which exhibit extremely potent anticancer activity in human cancer cell lines. A major breakthrough toward the synthesis of rigidin and various rigidin analogues has been the application of multicomponent reactions (MCRs). The rapid assembly of molecular diversity and flexibility displayed by MCRs makes it an attractive strategy for the preparation of rigidin-inspired small molecules. Furthermore, a number of rigidin-like 7-deazaxanthine compounds have been reported in the literature and the popularity of implementing MCRs to construct these 7-deazaxanthines is highlighted here. It is our hope that the synthetic methods described in this chapter will result in the further generation of rigidin-inspired compounds that will move on from being "hits" into "leads" in the medicinal chemistry drug discovery pipeline and potentially into anticancer therapeutics.
Collapse
Affiliation(s)
- Aletta E van der Westhuyzen
- Department of Chemistry and Polymer Science, University of Stellenbosch, Matieland, Stellenbosch, South Africa
| | - Liliya V Frolova
- Department of Chemistry, New Mexico Institute of Mining and Technology, Socorro, NM, United States
| | - Alexander Kornienko
- Department of Chemistry and Biochemistry, Texas State University, San Marcos, TX, United States
| | - Willem A L van Otterlo
- Department of Chemistry and Polymer Science, University of Stellenbosch, Matieland, Stellenbosch, South Africa.
| |
Collapse
|
15
|
Cawrse BM, Lapidus RS, Cooper B, Choi EY, Seley-Radtke KL. Anticancer Properties of Halogenated Pyrrolo[3,2-d]pyrimidines with Decreased Toxicity via N5 Substitution. ChemMedChem 2018; 13:178-185. [PMID: 29193845 PMCID: PMC5912934 DOI: 10.1002/cmdc.201700641] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2017] [Revised: 11/24/2017] [Indexed: 11/09/2022]
Abstract
Halogenated pyrrolo[3,2-d]pyrimidine analogues have shown antiproliferative activity in recent studies, with cell accumulation occurring in the G2 /M stage without apoptosis. However, the mechanism of action and pharmacokinetic (PK) profile of these compounds has yet to be determined. To investigate the PK profile of these compounds, a series of halogenated pyrrolo[3,2-d]pyrimidine compounds was synthesized and first tested for activity in various cancer cell lines followed by a mouse model. EC50 values ranged from 0.014 to 14.5 μm, and maximum tolerated doses (MTD) in mice were between 5 and 10 mg kg-1 . This indicates a wide variance in activity and toxicity that necessitates further study. To decrease toxicity, a second series of compounds was synthesized with N5-alkyl substitutions in an effort to slow the rate of metabolism, which was thought to be leading to the toxicity. The N-substituted compounds demonstrated comparable cell line activity (EC50 values between 0.83-7.3 μm) with significantly decreased toxicity (MTD=40 mg kg-1 ). Finally, the PK profile of the active N5-substituted compound shows a plasma half-life of 32.7 minutes, and rapid conversion into the parent unsubstituted analogue. Together, these data indicate that halogenated pyrrolo[3,2-d]pyrimidines present a promising lead into potent antiproliferative agents with tunable activity and toxicity, and rapid metabolism.
Collapse
Affiliation(s)
- Brian M Cawrse
- Department of Chemistry and Biochemistry, University of Maryland, Baltimore County, 1000 Hilltop Circle, Baltimore, MD, 21250, USA
| | - Rena S Lapidus
- Translational Laboratory Shared Service, University of Maryland School of Medicine, 655 West Baltimore Street, Baltimore, MD, 21201, USA
| | - Brandon Cooper
- Translational Laboratory Shared Service, University of Maryland School of Medicine, 655 West Baltimore Street, Baltimore, MD, 21201, USA
| | - Eun Yong Choi
- Translational Laboratory Shared Service, University of Maryland School of Medicine, 655 West Baltimore Street, Baltimore, MD, 21201, USA
| | - Katherine L Seley-Radtke
- Department of Chemistry and Biochemistry, University of Maryland, Baltimore County, 1000 Hilltop Circle, Baltimore, MD, 21250, USA
| |
Collapse
|
16
|
Castro-Gamero AM, Pezuk JA, Brassesco MS, Tone LG. G2/M inhibitors as pharmacotherapeutic opportunities for glioblastoma: the old, the new, and the future. Cancer Biol Med 2018; 15:354-374. [PMID: 30766748 PMCID: PMC6372908 DOI: 10.20892/j.issn.2095-3941.2018.0030] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023] Open
Abstract
Glioblastoma (GBM) is one of the deadliest tumors and has a median survival of 3 months if left untreated. Despite advances in rationally targeted pharmacological approaches, the clinical care of GBM remains palliative in intent. Since the majority of altered signaling cascades involved in cancer establishment and progression eventually affect cell cycle progression, an alternative approach for cancer therapy is to develop innovative compounds that block the activity of crucial molecules needed by tumor cells to complete cell division. In this context, we review promising ongoing and future strategies for GBM therapeutics aimed towards G2/M inhibition such as anti-microtubule agents and targeted therapy against G2/M regulators like cyclin-dependent kinases, Aurora inhibitors, PLK1, BUB, 1, and BUBR1, and survivin. Moreover, we also include investigational agents in the preclinical and early clinical settings. Although several drugs were shown to be gliotoxic, most of them have not yet entered therapeutic trials. The use of either single exposure or a combination with novel compounds may lead to treatment alternatives for GBM patients in the near future.
Collapse
Affiliation(s)
- Angel Mauricio Castro-Gamero
- Human Genetics Laboratory, Institute of Natural Sciences, Federal University of Alfenas (UNIFAL-MG), Alfenas 37130-001, Brazil
| | - Julia Alejandra Pezuk
- Biotechnology and Innovation in Health Program and Pharmacy Program, Anhanguera University São Paulo (UNIAN-SP), São Paulo 05145-200, Brazil
| | - María Sol Brassesco
- Department of Biology, Faculty of Philosophy, Sciences and Letters at Ribeirão Preto, University of São Paulo, Ribeirão Preto 14040-901, Brazil
| | - Luiz Gonzaga Tone
- Department of Pediatrics.,Department of Genetics, Ribeirão Preto School of Medicine, University of São Paulo, Ribeirão Preto 14049-900, Brazil
| |
Collapse
|
17
|
Belot V, Farran D, Jean M, Albalat M, Vanthuyne N, Roussel C. Steric Scale of Common Substituents from Rotational Barriers of N-(o-Substituted aryl)thiazoline-2-thione Atropisomers. J Org Chem 2017; 82:10188-10200. [DOI: 10.1021/acs.joc.7b01698] [Citation(s) in RCA: 39] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Vincent Belot
- Aix Marseille Univ, CNRS, Centrale Marseille,
iSm2, Marseille, France
| | - Daniel Farran
- Aix Marseille Univ, CNRS, Centrale Marseille,
iSm2, Marseille, France
| | - Marion Jean
- Aix Marseille Univ, CNRS, Centrale Marseille,
iSm2, Marseille, France
| | - Muriel Albalat
- Aix Marseille Univ, CNRS, Centrale Marseille,
iSm2, Marseille, France
| | - Nicolas Vanthuyne
- Aix Marseille Univ, CNRS, Centrale Marseille,
iSm2, Marseille, France
| | - Christian Roussel
- Aix Marseille Univ, CNRS, Centrale Marseille,
iSm2, Marseille, France
| |
Collapse
|
18
|
Zwergel C, Czepukojc B, Evain-Bana E, Xu Z, Stazi G, Mori M, Patsilinakos A, Mai A, Botta B, Ragno R, Bagrel D, Kirsch G, Meiser P, Jacob C, Montenarh M, Valente S. Novel coumarin- and quinolinone-based polycycles as cell division cycle 25-A and -C phosphatases inhibitors induce proliferation arrest and apoptosis in cancer cells. Eur J Med Chem 2017; 134:316-333. [DOI: 10.1016/j.ejmech.2017.04.012] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2016] [Revised: 04/03/2017] [Accepted: 04/06/2017] [Indexed: 01/06/2023]
|
19
|
Nickel J, Fernández M, Klier L, Knochel P. Synthesis of Pyrrolo[2,3-d
]pyrimidines by Copper-Mediated Carbomagnesiations of N
-Sulfonyl Ynamides and Application to the Preparation of Rigidin A and a 7-Azaserotonin Derivative. Chemistry 2016; 22:14397-400. [DOI: 10.1002/chem.201602519] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2016] [Indexed: 11/06/2022]
Affiliation(s)
- Johannes Nickel
- Ludwig Maximilians-Universität München; Department Chemie; Butenandtstrasse 5-13, Haus F 81377 München Germany
| | - Maitane Fernández
- Ludwig Maximilians-Universität München; Department Chemie; Butenandtstrasse 5-13, Haus F 81377 München Germany
| | - Lydia Klier
- Ludwig Maximilians-Universität München; Department Chemie; Butenandtstrasse 5-13, Haus F 81377 München Germany
| | - Paul Knochel
- Ludwig Maximilians-Universität München; Department Chemie; Butenandtstrasse 5-13, Haus F 81377 München Germany
| |
Collapse
|
20
|
Panayides JL, Mathieu V, Banuls LMY, Apostolellis H, Dahan-Farkas N, Davids H, Harmse L, Rey MEC, Green IR, Pelly SC, Kiss R, Kornienko A, van Otterlo WAL. Synthesis and in vitro growth inhibitory activity of novel silyl- and trityl-modified nucleosides. Bioorg Med Chem 2016; 24:2716-24. [PMID: 27157005 DOI: 10.1016/j.bmc.2016.04.036] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2016] [Revised: 04/14/2016] [Accepted: 04/19/2016] [Indexed: 12/17/2022]
Abstract
Seventeen silyl- and trityl-modified (5'-O- and 3',5'-di-O-) nucleosides were synthesized with the aim of investigating the in vitro antiproliferative activities of these nucleoside derivatives. A subset of the compounds was evaluated at a fixed concentration of 100μM against a small panel of tumor cell lines (HL-60, K-562, Jurkat, Caco-2 and HT-29). The entire set was also tested at varying concentrations against two human glioma lines (U373 and Hs683) to obtain GI50 values, with the best results being values of ∼25μM.
Collapse
Affiliation(s)
- Jenny-Lee Panayides
- Molecular Sciences Institute, School of Chemistry, University of the Witwatersrand, PO Wits, Johannesburg 2050, South Africa; Pioneering Health Sciences, CSIR Biosciences, PO Box 395, Pretoria 0001, South Africa
| | - Véronique Mathieu
- Laboratoire de Cancérologie et de Toxicologie Expérimentale, Faculté de Pharmacie, Université Libre de Bruxelles, Brussels, Belgium
| | - Laetitia Moreno Y Banuls
- Laboratoire de Cancérologie et de Toxicologie Expérimentale, Faculté de Pharmacie, Université Libre de Bruxelles, Brussels, Belgium
| | - Helen Apostolellis
- Department of Pharmacy and Pharmacology, Faculty of Health Sciences, University of the Witwatersrand, PO Wits, Johannesburg 2050, South Africa
| | - Nurit Dahan-Farkas
- Department of Pharmacy and Pharmacology, Faculty of Health Sciences, University of the Witwatersrand, PO Wits, Johannesburg 2050, South Africa
| | - Hajierah Davids
- Department of Pharmacy and Pharmacology, Faculty of Health Sciences, University of the Witwatersrand, PO Wits, Johannesburg 2050, South Africa; Department of Biochemistry and Microbiology, Nelson Mandela Metropolitan University, PO Box 77000, Port Elizabeth 6031, South Africa
| | - Leonie Harmse
- Department of Pharmacy and Pharmacology, Faculty of Health Sciences, University of the Witwatersrand, PO Wits, Johannesburg 2050, South Africa
| | - M E Christine Rey
- School of Molecular and Cellular Biology, University of the Witwatersrand, PO Wits, Johannesburg 2050, South Africa
| | - Ivan R Green
- Department of Chemistry and Polymer Science, Stellenbosch University, Stellenbosch, Matieland 7602, South Africa
| | - Stephen C Pelly
- Department of Chemistry and Polymer Science, Stellenbosch University, Stellenbosch, Matieland 7602, South Africa
| | - Robert Kiss
- Laboratoire de Cancérologie et de Toxicologie Expérimentale, Faculté de Pharmacie, Université Libre de Bruxelles, Brussels, Belgium
| | - Alexander Kornienko
- Department of Chemistry and Biochemistry, Texas State University, San Marcos, TX 78666, USA
| | - Willem A L van Otterlo
- Molecular Sciences Institute, School of Chemistry, University of the Witwatersrand, PO Wits, Johannesburg 2050, South Africa; Department of Chemistry and Polymer Science, Stellenbosch University, Stellenbosch, Matieland 7602, South Africa.
| |
Collapse
|
21
|
De Coen LM, Heugebaert TSA, García D, Stevens CV. Synthetic Entries to and Biological Activity of Pyrrolopyrimidines. Chem Rev 2015; 116:80-139. [DOI: 10.1021/acs.chemrev.5b00483] [Citation(s) in RCA: 109] [Impact Index Per Article: 12.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Affiliation(s)
- Laurens M. De Coen
- Department of Sustainable
Organic Chemistry and Technology, Ghent University, Coupure links
653, B-9000 Ghent, Belgium
| | - Thomas S. A. Heugebaert
- Department of Sustainable
Organic Chemistry and Technology, Ghent University, Coupure links
653, B-9000 Ghent, Belgium
| | - Daniel García
- Department of Sustainable
Organic Chemistry and Technology, Ghent University, Coupure links
653, B-9000 Ghent, Belgium
| | - Christian V. Stevens
- Department of Sustainable
Organic Chemistry and Technology, Ghent University, Coupure links
653, B-9000 Ghent, Belgium
| |
Collapse
|
22
|
Medellin DC, Zhou Q, Scott R, Hill RM, Frail SK, Dasari R, Ontiveros SJ, Pelly SC, van Otterlo WAL, Betancourt T, Shuster CB, Hamel E, Bai R, LaBarbera DV, Rogelj S, Frolova LV, Kornienko A. Novel Microtubule-Targeting 7-Deazahypoxanthines Derived from Marine Alkaloid Rigidins with Potent in Vitro and in Vivo Anticancer Activities. J Med Chem 2015; 59:480-5. [PMID: 26641132 DOI: 10.1021/acs.jmedchem.5b01426] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
Docking studies of tubulin-targeting C2-substituted 7-deazahypoxanthine analogues of marine alkaloid rigidins led to the design and synthesis of compounds containing linear C2-substituents. The C2-alkynyl analogue was found to have double- to single-digit nanomolar antiproliferative IC50 values and showed statistically significant tumor size reduction in a colon cancer mouse model at nontoxic concentrations. These results provide impetus and further guidance for the development of these rigidin analogues as anticancer agents.
Collapse
Affiliation(s)
- Derek C Medellin
- Department of Chemistry and Biochemistry, Texas State University , San Marcos, Texas 78666, United States
| | - Qiong Zhou
- Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus , Aurora, Colorado 80045, United States
| | - Robert Scott
- Department of Chemistry and Biochemistry, Texas State University , San Marcos, Texas 78666, United States
| | - R Matthew Hill
- Department of Chemistry and Biochemistry, Texas State University , San Marcos, Texas 78666, United States
| | - Sarah K Frail
- Departments of Chemistry and Biology, New Mexico Tech , Socorro, New Mexico 87801, United States
| | - Ramesh Dasari
- Department of Chemistry and Biochemistry, Texas State University , San Marcos, Texas 78666, United States
| | - Steven J Ontiveros
- Department of Biology, New Mexico State University , Las Cruces, New Mexico 88003, United States
| | - Stephen C Pelly
- Department of Chemistry and Polymer Science, Stellenbosch University , Stellenbosch, Western Cape, South Africa
| | - Willem A L van Otterlo
- Department of Chemistry and Polymer Science, Stellenbosch University , Stellenbosch, Western Cape, South Africa
| | - Tania Betancourt
- Department of Chemistry and Biochemistry, Texas State University , San Marcos, Texas 78666, United States.,Materials Science, Engineering, and Commercialization Program, Texas State University , San Marcos, Texas 78666, United States
| | - Charles B Shuster
- Department of Biology, New Mexico State University , Las Cruces, New Mexico 88003, United States
| | - Ernest Hamel
- Screening Technologies Branch, Developmental Therapeutics Program, National Cancer Institute, Frederick National Laboratory of Cancer Research, National Institutes of Health, Frederick, Maryland 21702, United States
| | - Ruoli Bai
- Screening Technologies Branch, Developmental Therapeutics Program, National Cancer Institute, Frederick National Laboratory of Cancer Research, National Institutes of Health, Frederick, Maryland 21702, United States
| | - Daniel V LaBarbera
- Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus , Aurora, Colorado 80045, United States
| | - Snezna Rogelj
- Departments of Chemistry and Biology, New Mexico Tech , Socorro, New Mexico 87801, United States
| | - Liliya V Frolova
- Departments of Chemistry and Biology, New Mexico Tech , Socorro, New Mexico 87801, United States
| | - Alexander Kornienko
- Department of Chemistry and Biochemistry, Texas State University , San Marcos, Texas 78666, United States
| |
Collapse
|
23
|
Dasari R, De Carvalho A, Medellin DC, Middleton KN, Hague F, Volmar MNM, Frolova LV, Rossato MF, De La Chapa JJ, Dybdal-Hargreaves NF, Pillai A, Mathieu V, Rogelj S, Gonzales CB, Calixto JB, Evidente A, Gautier M, Munirathinam G, Glass R, Burth P, Pelly SC, van Otterlo WAL, Kiss R, Kornienko A. Synthetic and Biological Studies of Sesquiterpene Polygodial: Activity of 9-Epipolygodial against Drug-Resistant Cancer Cells. ChemMedChem 2015; 10:2014-26. [PMID: 26434977 PMCID: PMC4831215 DOI: 10.1002/cmdc.201500360] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2015] [Indexed: 12/18/2022]
Abstract
Polygodial, a terpenoid dialdehyde isolated from Polygonum hydropiper L., is a known agonist of the transient receptor potential vanilloid 1 (TRPV1). In this investigation a series of polygodial analogues were prepared and investigated for TRPV1-agonist and anticancer activities. These experiments led to the identification of 9-epipolygodial, which has antiproliferative potency significantly exceeding that of polygodial. 9-Epipolygodial was found to maintain potency against apoptosis-resistant cancer cells as well as those displaying the multidrug-resistant (MDR) phenotype. In addition, the chemical feasibility for the previously proposed mechanism of action of polygodial, involving the formation of a Paal-Knorr pyrrole with a lysine residue on the target protein, was demonstrated by the synthesis of a stable polygodial pyrrole derivative. These studies reveal rich chemical and biological properties associated with polygodial and its direct derivatives. These compounds should inspire further work in this area aimed at the development of new pharmacological agents, or the exploration of novel mechanisms of covalent modification of biological molecules with natural products.
Collapse
Affiliation(s)
- Ramesh Dasari
- Department of Chemistry and Biochemistry, Texas State University, San Marcos, TX, 78666, USA
| | - Annelise De Carvalho
- Laboratoire de Cancérologie et de Toxicologie Expérimentale, Faculté de Pharmacie, Université Libre de Bruxelles, 1050, Brussels, Belgium
| | - Derek C Medellin
- Department of Chemistry and Biochemistry, Texas State University, San Marcos, TX, 78666, USA
| | - Kelsey N Middleton
- Department of Chemistry and Biochemistry, Texas State University, San Marcos, TX, 78666, USA
| | - Frédéric Hague
- Laboratoire de Physiologie Cellulaire et Moléculaire, Faculté des Sciences, Université de Picardie Jules Verne, 80000, Amiens, France
| | - Marie N M Volmar
- Neurosurgical Research, University Clinics Munich, Marchioninistr. 15, 81377, Munich, Germany
| | - Liliya V Frolova
- Departments of Chemistry and Biology, New Mexico Institute of Mining and Technology, 801 Leroy Place, Socorro, NM, 87801, USA
| | - Mateus F Rossato
- Center of Innovation and Preclinical Studies, Av. Luiz Boiteux Piazza 1302, Cachoeira do Bom Jesus, Florianópolis, SC, 88056-000, Brazil
- Department of Pharmacology, Federal University of Santa Catarina, Florianópolis, SC, Brazil
| | - Jorge J De La Chapa
- Department of Comprehensive Dentistry, Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, TX, 78229, USA
| | - Nicholas F Dybdal-Hargreaves
- Department of Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, TX, 78229, USA
| | - Akshita Pillai
- Department of Biomedical Sciences, College of Medicine, University of Illinois, 1601 Parkview Ave., Rockford, IL, 61107, USA
| | - Véronique Mathieu
- Laboratoire de Cancérologie et de Toxicologie Expérimentale, Faculté de Pharmacie, Université Libre de Bruxelles, 1050, Brussels, Belgium
| | - Snezna Rogelj
- Departments of Chemistry and Biology, New Mexico Institute of Mining and Technology, 801 Leroy Place, Socorro, NM, 87801, USA
| | - Cara B Gonzales
- Department of Comprehensive Dentistry, Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, TX, 78229, USA
| | - João B Calixto
- Center of Innovation and Preclinical Studies, Av. Luiz Boiteux Piazza 1302, Cachoeira do Bom Jesus, Florianópolis, SC, 88056-000, Brazil
- Department of Pharmacology, Federal University of Santa Catarina, Florianópolis, SC, Brazil
| | - Antonio Evidente
- Dipartimento di Scienze Chimiche, Università di Napoli Federico II, Complesso Universitario Monte Sant'Angelo, Via Cintia 4, 80126, Napoli, Italy
| | - Mathieu Gautier
- Laboratoire de Physiologie Cellulaire et Moléculaire, Faculté des Sciences, Université de Picardie Jules Verne, 80000, Amiens, France
| | - Gnanasekar Munirathinam
- Department of Biomedical Sciences, College of Medicine, University of Illinois, 1601 Parkview Ave., Rockford, IL, 61107, USA
| | - Rainer Glass
- Neurosurgical Research, University Clinics Munich, Marchioninistr. 15, 81377, Munich, Germany
| | - Patricia Burth
- Departamento de Biologia Celular e Molecular, Instituto de Biologia, Universidade Federal Fluminense, Outeiro de São João Batista, s/n Campus do Valonguinho, Centro-Niterói, RJ, 24020-140, Brazil
| | - Stephen C Pelly
- Department of Chemistry and Polymer Science, Stellenbosch University, Stellenbosch, Private Bag X1, Matieland, 7602, South Africa
| | - Willem A L van Otterlo
- Department of Chemistry and Polymer Science, Stellenbosch University, Stellenbosch, Private Bag X1, Matieland, 7602, South Africa
| | - Robert Kiss
- Laboratoire de Cancérologie et de Toxicologie Expérimentale, Faculté de Pharmacie, Université Libre de Bruxelles, 1050, Brussels, Belgium
| | - Alexander Kornienko
- Department of Chemistry and Biochemistry, Texas State University, San Marcos, TX, 78666, USA.
| |
Collapse
|
24
|
Dasari R, Masi M, Lisy R, Ferdérin M, English LR, Cimmino A, Mathieu V, Brenner AJ, Kuhn JG, Whitten ST, Evidente A, Kiss R, Kornienko A. Fungal metabolite ophiobolin A as a promising anti-glioma agent: In vivo evaluation, structure-activity relationship and unique pyrrolylation of primary amines. Bioorg Med Chem Lett 2015; 25:4544-8. [PMID: 26341136 PMCID: PMC4592837 DOI: 10.1016/j.bmcl.2015.08.066] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2015] [Revised: 08/20/2015] [Accepted: 08/24/2015] [Indexed: 02/04/2023]
Abstract
Glioblastoma, the most common form of malignant primary brain tumor, is characterized by resistance to apoptosis, which is largely responsible for the low effectiveness of the classical chemotherapeutic approaches based on apoptosis induction in cancer cells. Previously, a fungal secondary metabolite ophiobolin A was found to have significant activity against apoptosis-resistant glioblastoma cells through the induction of a non-apoptotic cell death, thus, offering an innovative strategy to combat this type of cancer. The current work describes the results of a preliminary evaluation of ophiobolin A in an in vivo glioblastoma model and its chemical derivatization to establish first synthetically generated structure-activity relationship. The synthetic work has also led to the discovery of a unique reaction of ophiobolin A with primary amines suggesting the possibility of pyrrolylation of lysine residues on its intracellular target protein(s).
Collapse
Affiliation(s)
- Ramesh Dasari
- Department of Chemistry and Biochemistry, Texas State University, San Marcos, TX 78666, USA
| | - Marco Masi
- Dipartimento di Scienze Chimiche, Università di Napoli Federico II, Complesso Universitario Monte Sant'Angelo, Via Cintia 4, 80126 Napoli, Italy
| | - Romana Lisy
- Laboratoire de Cancérologie et de Toxicologie Expérimentale, Faculté de Pharmacie, Université Libre de Bruxelles, Brussels, Belgium
| | - Marlène Ferdérin
- Laboratoire de Cancérologie et de Toxicologie Expérimentale, Faculté de Pharmacie, Université Libre de Bruxelles, Brussels, Belgium
| | - Lance R English
- Department of Chemistry and Biochemistry, Texas State University, San Marcos, TX 78666, USA
| | - Alessio Cimmino
- Dipartimento di Scienze Chimiche, Università di Napoli Federico II, Complesso Universitario Monte Sant'Angelo, Via Cintia 4, 80126 Napoli, Italy
| | - Véronique Mathieu
- Laboratoire de Cancérologie et de Toxicologie Expérimentale, Faculté de Pharmacie, Université Libre de Bruxelles, Brussels, Belgium
| | - Andrew J Brenner
- Cancer Therapy and Research Center, The University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA
| | - John G Kuhn
- Cancer Therapy and Research Center, The University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA
| | - Steven T Whitten
- Department of Chemistry and Biochemistry, Texas State University, San Marcos, TX 78666, USA
| | - Antonio Evidente
- Dipartimento di Scienze Chimiche, Università di Napoli Federico II, Complesso Universitario Monte Sant'Angelo, Via Cintia 4, 80126 Napoli, Italy
| | - Robert Kiss
- Laboratoire de Cancérologie et de Toxicologie Expérimentale, Faculté de Pharmacie, Université Libre de Bruxelles, Brussels, Belgium
| | - Alexander Kornienko
- Department of Chemistry and Biochemistry, Texas State University, San Marcos, TX 78666, USA.
| |
Collapse
|
25
|
Dasari R, De Carvalho A, Medellin DC, Middleton KN, Hague F, Volmar MNM, Frolova LV, Rossato MF, De La Chapa JJ, Dybdal-Hargreaves NF, Pillai A, Kälin RE, Mathieu V, Rogelj S, Gonzales CB, Calixto JB, Evidente A, Gautier M, Munirathinam G, Glass R, Burth P, Pelly SC, van Otterlo WAL, Kiss R, Kornienko A. Wittig derivatization of sesquiterpenoid polygodial leads to cytostatic agents with activity against drug resistant cancer cells and capable of pyrrolylation of primary amines. Eur J Med Chem 2015; 103:226-37. [PMID: 26360047 DOI: 10.1016/j.ejmech.2015.08.047] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2015] [Revised: 08/22/2015] [Accepted: 08/24/2015] [Indexed: 12/13/2022]
Abstract
Many types of cancer, including glioma, melanoma, non-small cell lung cancer (NSCLC), among others, are resistant to proapoptotic stimuli and thus poorly responsive to current therapies based on the induction of apoptosis in cancer cells. The current investigation describes the synthesis and anticancer evaluation of unique C12-Wittig derivatives of polygodial, a sesquiterpenoid dialdehyde isolated from Persicaria hydropiper (L.) Delabre. These compounds were found to undergo an unprecedented pyrrole formation with primary amines in a chemical model system, a reaction that could be relevant in the biological environment and lead to the pyrrolation of lysine residues in the target proteins. The anticancer evaluation of these compounds revealed their promising activity against cancer cells displaying various forms of drug resistance, including resistance to proapoptotic agents. Mechanistic studies indicated that compared to the parent polygodial, which displays fixative general cytotoxic action against human cells, the C12-Wittig derivatives exerted their antiproliferative action mainly through cytostatic effects explaining their activity against apoptosis-resistant cancer cells. The possibility for an intriguing covalent modification of proteins through a novel pyrrole formation reaction, as well as useful activities against drug resistant cancer cells, make the described polygodial-derived chemical scaffold an interesting new chemotype warranting thorough investigation.
Collapse
Affiliation(s)
- Ramesh Dasari
- Department of Chemistry and Biochemistry, Texas State University, San Marcos, TX 78666, USA
| | - Annelise De Carvalho
- Laboratoire de Cancérologie et de Toxicologie Expérimentale, Faculté de Pharmacie, Université Libre de Bruxelles, Brussels, Belgium
| | - Derek C Medellin
- Department of Chemistry and Biochemistry, Texas State University, San Marcos, TX 78666, USA
| | - Kelsey N Middleton
- Department of Chemistry and Biochemistry, Texas State University, San Marcos, TX 78666, USA
| | - Frédéric Hague
- Laboratoire de Physiologie Cellulaire et Moléculaire, Faculté des Sciences, Université de Picardie Jules Verne, Amiens, France
| | - Marie N M Volmar
- Neurosurgical Research, University Clinics Munich, Marchioninistr. 15, 81377 Munich, Germany
| | - Liliya V Frolova
- Department of Chemistry, New Mexico Tech, 801 Leroy Place, Socorro, NM 87801, USA; Department of Biology, New Mexico Tech, 801 Leroy Place, Socorro, NM 87801, USA
| | - Mateus F Rossato
- Center of Innovation and Preclinical Studies, Luiz Boiteux Piazza 1302, Cachoeira do Bom Jesus, Brazil; Department of Pharmacology, UFSC, Florianópolis SC 88.056-000, Brazil
| | - Jorge J De La Chapa
- Department of Comprehensive Dentistry, Cancer Therapy and Research Center, UTHSCSA, San Antonio, TX 78229, USA
| | | | - Akshita Pillai
- Department of Biomedical Sciences, University of Illinois, College of Medicine, 1601 Parkview Ave, Rockford, IL 61107, USA
| | - Roland E Kälin
- Neurosurgical Research, University Clinics Munich, Marchioninistr. 15, 81377 Munich, Germany
| | - Véronique Mathieu
- Laboratoire de Cancérologie et de Toxicologie Expérimentale, Faculté de Pharmacie, Université Libre de Bruxelles, Brussels, Belgium
| | - Snezna Rogelj
- Department of Chemistry, New Mexico Tech, 801 Leroy Place, Socorro, NM 87801, USA; Department of Biology, New Mexico Tech, 801 Leroy Place, Socorro, NM 87801, USA
| | - Cara B Gonzales
- Department of Comprehensive Dentistry, Cancer Therapy and Research Center, UTHSCSA, San Antonio, TX 78229, USA
| | - João B Calixto
- Center of Innovation and Preclinical Studies, Luiz Boiteux Piazza 1302, Cachoeira do Bom Jesus, Brazil; Department of Pharmacology, UFSC, Florianópolis SC 88.056-000, Brazil
| | - Antonio Evidente
- Dipartimento di Scienze Chimiche, Università di Napoli Federico II, Complesso Universitario Monte Sant'Angelo, Via Cintia 4, 80126 Napoli, Italy
| | - Mathieu Gautier
- Laboratoire de Physiologie Cellulaire et Moléculaire, Faculté des Sciences, Université de Picardie Jules Verne, Amiens, France
| | - Gnanasekar Munirathinam
- Department of Biomedical Sciences, University of Illinois, College of Medicine, 1601 Parkview Ave, Rockford, IL 61107, USA
| | - Rainer Glass
- Neurosurgical Research, University Clinics Munich, Marchioninistr. 15, 81377 Munich, Germany
| | - Patricia Burth
- Departamento de Biologia Celular e Molecular, Instituto de Biologia, Universidade Federal Fluminense, Outeiro de São João Batista, s/n° Campus do Valonguinho, Centro-Niterói, RJ 24020-140, Brazil
| | - Stephen C Pelly
- Department of Chemistry and Polymer Science, Stellenbosch University, Stellenbosch, Private Bag X1, Matieland, 7602, South Africa
| | - Willem A L van Otterlo
- Department of Chemistry and Polymer Science, Stellenbosch University, Stellenbosch, Private Bag X1, Matieland, 7602, South Africa
| | - Robert Kiss
- Laboratoire de Cancérologie et de Toxicologie Expérimentale, Faculté de Pharmacie, Université Libre de Bruxelles, Brussels, Belgium
| | - Alexander Kornienko
- Department of Chemistry and Biochemistry, Texas State University, San Marcos, TX 78666, USA.
| |
Collapse
|
26
|
Anticancer properties of lamellarins. Mar Drugs 2015; 13:1105-23. [PMID: 25706633 PMCID: PMC4377975 DOI: 10.3390/md13031105] [Citation(s) in RCA: 98] [Impact Index Per Article: 10.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2014] [Revised: 12/24/2014] [Accepted: 02/13/2015] [Indexed: 12/12/2022] Open
Abstract
In 1985 the first lamellarins were isolated from a small oceanic sea snail. Today, more than 50 lamellarins have been inventoried and numerous derivatives synthesized and tested as antiviral or anticancer agents. The lead compound in the family is lamellarin D, characterized as a potent inhibitor of both nuclear and mitochondrial topoisomerase I but also capable of directly interfering with mitochondria to trigger cancer cell death. The pharmacology and chemistry of lamellarins are discussed here and the mechanistic portrait of lamellarin D is detailed. Lamellarins frequently serve as a starting point in the design of anticancer compounds. Extensive efforts have been devoted to create novel structures as well as to improve synthetic methods, leading to lamellarins and related pyrrole-derived marine alkaloids.
Collapse
|